Clinical Trials Browser

Platinum-resistant Ovarian Cancer × anlotinib × Clear all

NCT05736952 2023-05-11

Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer

Phase 2 Withdrawn

Platinum-resistant Ovarian Cancer

NCT04376073 2020-11-25

ANNIE

Phase 2 Unknown

Platinum-resistant Ovarian Cancer